Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.50 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.50 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CFTR | P13569 | 4/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | RBP4 | P02753 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8609816 | 0.86 | SLC9A1 (0.45) | CTSSTAS1R3TAS1R1TAS1R2KAT6A | |
| SCHEMBL22831692 | 0.84 | CFTR (0.49) | CTSSMRGPRX4LMNAGAATSHR | |
| SCHEMBL45490 | 0.84 | LMNA (0.59) | LMNAGAATSHRCFTRSLC6A4 | |
| SCHEMBL1401560 | 0.83 | TSHR (0.57) | LMNATSHRCFTRSLC6A4SLC6A3 | |
| SCHEMBL726068 | 0.83 | TAS2R14 (0.54) | CTSSLMNAGAATSHRCFTR | |
| SCHEMBL1508457 | 0.83 | LMNA (0.50) | CTSSLMNAGAATSHRCFTR | |
| SCHEMBL10391427 | 0.81 | LMNA (0.45) | LMNAGAATSHRCFTRALDH1A1 | |
| SCHEMBL4119115 | 0.81 | CTSS (0.56) | CTSSLMNAGAATSHRCFTR | |
| SCHEMBL22403860 | 0.81 | TAS2R14 (0.52) | LMNAGAATSHRCFTRSLC6A3 | |
| SCHEMBL3531721 | 0.81 | CFTR (0.51) | CTSSLMNAGAATSHRCFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743079-A2 | APOL1 INHIBITORS AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743078-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | MAZE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| CN-119325476-A | Nitrogen-containing condensed 2, 3-dihydroquinazolinone compounds as NAV1.8 inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2025-01-17 | — | — | CN | disclosed |
| WO-2025015106-A2 | APOL1 INHIBITORS AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2025015104-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| EP-3555088-B1 | BISARYL AMIDES AS NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-11-24 | — | — | EP | disclosed |
| EP-3555088-B1 | BISARYL AMIDES AS NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-11-24 | — | — | EP | disclosed |
| US-11078216-B2 | Bisaryl amides as NRF2 activators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-03 | — | — | US | disclosed |
| US-11078216-B2 | Bisaryl amides as NRF2 activators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-03 | — | — | US | disclosed |
| WO-2013177349-A2 | QUINAZOLINEDIONES AS TANKYRASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-11-28 | — | — | WO | disclosed |
| EP-1397364-B1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | LILLY CO ELI (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-0779281-B1 | ISOXAZOLES | SANKYO CO (JP) | 2003-10-29 | — | — | EP | disclosed |
| CN-1098843-C | Isoxazoles | SANKYO CO (JP) | 2003-01-15 | — | — | CN | disclosed |
| CN-1064955-C | Fluorine-containing benzoylguanidines | MERCK PATENT GMBH (DE) | 2001-04-25 | — | — | CN | disclosed |
| US-6096771-A | ISOXAZOLE DERIVATIVES EXHIBITING EXCELLENT TYPE B AND TYPE A MONOAMINE OXIDASE INHIBITORY ACTIVITIES, THEREFORE USEFUL FOR PREVENTING PARKINSON'S DISEASE, DEPRESSION AND ALZHEIMER'S DISEASE | SANKYO COMPANY, LIMITED (JP) | 2000-08-01 | — | — | US | disclosed |
| US-5965591-A | MONOAMINE OXIDASE INHIBITOR; FOR PROPHYLAXIS AND TREATING PARKINSON'S DISEASE, DEPRESSION AND ALZHEIMER'S DISEASE | SANKYO COMPANY, LIMITED (JP) | 1999-10-12 | — | — | US | disclosed |
| CN-1162957-A | Isoxazole derivatives | SANKYO CO (JP) | 1997-10-22 | — | — | CN | disclosed |
| EP-0779281-A1 | ISOXAZOLES | SANKYO COMPANY LIMITED (JP) | 1997-06-18 | — | — | EP | disclosed |
| CN-1143632-A | Fluorine-containing benzoylguanidines | MERCK PATENT GMBH (DE) | 1997-02-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078216-B2 | Bisaryl amides as NRF2 activators | NFE2L2, KEAP1, NQO1 | CTSS 2416/4885TAS1R3 4226/4885TAS1R1 4440/4885 |
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | APOL1, APOB, LDLR | CTSS 1051/4885TAS1R3 1794/4885TAS1R1 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.